TNGX
Tango Therapeutics Inc.
Company Overview
| Mkt Cap | $1.05B | Price | $27.97 |
| Volume | 12.10M | Change | -13.38% |
| P/E Ratio | -10.3 | Open | $31.10 |
| Revenue | $62.4M | Prev Close | $32.29 |
| Net Income | $-101.6M | 52W Range | $4.40 - $32.79 |
| Div Yield | N/A | Target | $40.45 |
| Overall | 67 | Value | 45 |
| Quality | 65 | Technical | 91 |
No chart data available
About Tango Therapeutics Inc.
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors; TNG462, which is in Phase 1/2 clinical trial for non- central nervous system cancers including pancreatic and lung cancer; TNG456, a brain-penetrant PRMT5 inhibitor, for central nervous system cancers including glioblastoma; and TNG260, a co-repressor of repressor element-1 silencing transcription (CoREST) inhibitor to reverse the immune evasion effect of STK11 loss-of-function mutations. The company has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts.
Latest News
Tango Therapeutics Announces Major Underwritten Equity Offering
Tango Therapeutics Highlights Promising Vopimetostat Combination Data
Stifel Nicolaus Sticks to Their Buy Rating for Tango Therapeutics (TNGX)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | TNGX | $27.97 | -13.4% | 12.10M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |